{"doi":"10.34067/kid.0000001105","title":"Ergothioneine Depletion in Peritoneal Dialysis","abstract":"KEY POINTS: Hemodialysis has been shown to greatly deplete ergothioneine, a diet-derived antioxidant. Peritoneal dialysis, which provides lower clearance of solutes, also depletes ergothioneine but to a lesser extent than hemodialysis. Whether ergothioneine repletion benefits people receiving dialysis remains to be tested. BACKGROUND: Dialysis may deplete the body of valuable solutes. We previously found that the diet-derived antioxidant ergothioneine was markedly depleted in patients on hemodialysis. Standard peritoneal dialysis (PD) prescriptions provide lower clearance of small molecules than standard hemodialysis prescriptions. We, therefore, tested whether ergothioneine would be depleted in patients on PD but to a lesser degree than in patients on hemodialysis. METHODS: Blood levels of ergothioneine were compared in 16 patients on PD, 16 patients on hemodialysis, and 15 controls with normal kidney function. Levels were measured using liquid chromatography-mass spectrometry in plasma and also in erythrocytes in which ergothioneine is normally highly concentrated. Ergothioneine clearances by PD and hemodialysis were also compared. RESULTS: Erythrocyte ergothioneine levels were much lower in both patients on PD and patients on hemodialysis than controls. The erythrocyte levels in patients on PD averaged 34% of those of controls, whereas levels in patients on hemodialysis averaged only 10% of those of controls. Plasma ergothioneine levels in patients on dialysis were also lower than controls. The time-averaged clearance of ergothioneine was lower with PD than with hemodialysis, so that a standard PD regimen would remove less ergothioneine daily than a standard hemodialysis regimen at a given plasma level. CONCLUSIONS: The antioxidant ergothioneine is depleted in patients on PD but to a lesser extent than in patients on hemodialysis. Benefits of ergothioneine repletion in patients on dialysis remain to be assessed.","journal":"Kidney360","year":2025,"id":549542,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9538,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1262316,"name":"Josef K. Suba","orcid":"0000-0001-6754-1299","position":1,"is_corresponding":false},{"id":703547,"name":"Nhat M. Pham","orcid":"0000-0002-4555-0124","position":2,"is_corresponding":false},{"id":1443752,"name":"Graham E. Abra","orcid":"0000-0003-0921-3902","position":3,"is_corresponding":false},{"id":1443753,"name":"Margaret K. Yu","orcid":"0009-0008-4137-0848","position":4,"is_corresponding":false},{"id":391268,"name":"Tammy L. Sirich","orcid":"0000-0001-5587-8193","position":5,"is_corresponding":false},{"id":1262317,"name":"Lindsey S. Keo","orcid":"0009-0009-7742-4913","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:54:07.823422Z","pmid":"41411056","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}